Results from the ADAPT SERON Clinical Trial of Efgartigimod IV in Patients With Seronegative Generalized Myasthenia Gravis by Madaline Spencer| Published on: Jun 5, 2026

Results from the ADAPT SERON Clinical Trial of Efgartigimod IV in Patients With Seronegative Generalized Myasthenia Gravis by Madaline Spencer| Published on: Jun 5, 2026 James Howard Jr., MD, Professor of Neurology at the University of North Carolina at Chapel Hill, discusses results from the ADAPT SERON clinical trial of efgartigimod IV in patients with seronegative generalized myasthenia gravis (gMG). Data from this trial was pivotal in efgartigimod’s recent FDA approval. https://checkrare.com/results-from-the-adapt-seron-clinical-trial-of-efgartigimod-iv-in-patients-with-seronegative-generalized-myasthenia-gravis/